Department of Physical Medicine and Rehabilitation, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Department of Rehabilitation and Regenerative Medicine, New York-Presbyterian Hospital - Columbia and Cornell, New York, NY, USA.
Curr Pain Headache Rep. 2023 Dec;27(12):811-820. doi: 10.1007/s11916-023-01185-4. Epub 2023 Oct 28.
The aim of this review is to educate healthcare professionals regarding buprenorphine for the use of opioid use disorder (OUD) as well as for chronic pain management. This review provides physicians and practitioners with updated information regarding the distinct characteristics and intricacies of prescribing buprenorphine.
Buprenorphine is approved by the US Food and Drug Administration (FDA) for acute pain, chronic pain, opioid use disorder (OUD), and opioid dependence. When compared to most other opioids, buprenorphine offers superior patient tolerability, an excellent half-life, and minimal respiratory depression. Buprenorphine does have notable side effects as well as pharmacokinetic properties that require special attention, especially if patients require future surgical interventions. Many physicians are not trained to initiate or manage patients on buprenorphine. However, buprenorphine offers a potentially safer alternative for medication management for patients who require chronic opioid therapy for pain or have OUD. This review provides updated information on buprenorphine for both chronic pain and OUD.
目的：本文旨在为医疗保健专业人员提供有关丁丙诺啡的教育，包括其在阿片类药物使用障碍（OUD）和慢性疼痛管理中的应用。本文为医生和从业人员提供了有关丁丙诺啡的独特特征和复杂性的最新信息。
发现：丁丙诺啡已获得美国食品和药物管理局（FDA）批准，可用于治疗急性疼痛、慢性疼痛、阿片类药物使用障碍（OUD）和阿片类药物依赖。与大多数其他阿片类药物相比，丁丙诺啡具有更好的患者耐受性、优异的半衰期和最小的呼吸抑制作用。丁丙诺啡也有显著的副作用和药代动力学特性，需要特别注意，特别是如果患者需要未来的手术干预。许多医生没有接受过启动或管理丁丙诺啡患者的培训。然而，对于需要慢性阿片类药物治疗疼痛或患有 OUD 的患者，丁丙诺啡提供了一种潜在更安全的药物管理替代方案。本文为慢性疼痛和 OUD 患者提供了丁丙诺啡的最新信息。
